|Articles|November 18, 2008

Ginkgo Biloba Does Not Prevent Dementia, Study Concludes

Ginkgo biloba does not eliminate or prevent the progression of dementia or Alzheimer\'s, according to a new study published in the Journal of the American Medical Association (Chicago).

Ginkgo biloba does not eliminate or prevent the progression of dementia or Alzheimer's, according to a new study published in the Journal of the American Medical Association (Chicago).

The study enrolled 3,069 people between the ages of 75 and 96; half took a placebo while the other half took 240 milligrams a day of the ginkgo extract EGb 761, the extract used in products sold by Nature's Way (Springville, Utah).

At the end of the study, 277 people who took ginkgo were diagnosed with dementia, compared with 246 in the placebo group. The study also says the ginkgo group had 257 cases of Alzheimer's, compared to 220 in the placebo group.

"No one is more disappointed that we didn't have any traction in slowing down the disease than the group that did the study," said Steven T. DeKosky MD, the neurologist who led the trial.

"We did show it was fairly safe -- that is of some reassurance," said DeKosky, also dean of the University of Virginia Medical School. He said the only harm from gingko could be "spending money on something that may not be useful."

French researchers are currently using a much larger study pool-- 2,854 people over the age of 70 already suffering from memory problems. The results of that clinical trial will be available in 2010.

"That may show an effect that was missed in this study," said Maria C. Carrillo, director of medical and scientific relations for the Alzheimer Association (Chicago).

But Lon S. Schneider MD, a geriatric psychiatrist at USC (Los Angeles) said there’s no doubt that antioxidants protect neurons, however “we can make it work in animals, but we can't seem to make this work in humans."


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.